Home - Abcuro

Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease

news

Abcuro Appoints George Eldridge as Chief Financial Officer

August 18, 2025

Company further strengthens leadership team, with Mr. Eldridge bringing over 30 years of finance experience across biotechnology industry Newton, Massachusetts, August 18, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of George Eldridge as

August 18, 2025

Abcuro Appoints George Eldridge as Chief Financial OfficerPress Releases

Targeting Highly Cytotoxic T Cells

Highly cytotoxic T cells have been implicated as mediators of tissue damage in many autoimmune diseases

Ulviprubart in Autoimmune Disorders

Ulviprubart, an investigational monoclonal antibody, selectively depletes highly cytotoxic T cells

Inclusion Body Myositis

Inclusion body myositis (IBM) is a debilitating chronic, progressive disorder in which muscle is destroyed by highly cytotoxic T cells